Antibody-mediated rejection of the liver allograft: An update and a clinico-pathological perspective

J Hepatol. 2021 Nov;75(5):1203-1216. doi: 10.1016/j.jhep.2021.07.027. Epub 2021 Jul 31.

Abstract

Antibody-mediated rejection after liver transplantation is an under-recognised cause of allograft injury. While definitions of acute and chronic antibody-mediated rejection have increased clinical awareness, timely identification and management of antibody-mediated rejection remain difficult because of complexities in diagnosis and histopathology, lack of treatment protocols, and unclear long-term outcomes. While recent cohort studies assessing the importance of donor-specific antibodies have aided in its diagnosis, literature on the treatment of antibody-mediated rejection in liver transplantation remain limited to case reports and small series. Further increasing the awareness and timely recognition of antibody-mediated rejection post-liver transplantation is crucial in order to stimulate future research and the development of protocols for its diagnosis and treatment. This review will summarise recent advances in the clinical diagnosis and treatment of antibody-mediated rejection in liver transplantation, as well as some of the histopathologic features (on liver biopsy tissue) of acute and chronic antibody-mediated rejection.

Keywords: HLA; antibody-mediated rejection; donor-specific antibody; histology; liver transplantation.

Publication types

  • Review

MeSH terms

  • Allografts / immunology
  • Allografts / pathology
  • Antibodies / immunology*
  • Antibodies / metabolism
  • Biopsy / methods
  • Humans
  • Liver Transplantation / methods
  • Liver Transplantation / statistics & numerical data
  • Transplantation Tolerance / immunology*
  • Treatment Outcome

Substances

  • Antibodies